Growth hormone deficiency after localized ganglioneuroblastoma: A case report.
Growth hormone deficiency (GHD) related to standard dose chemotherapy has rarely been described. We report on a case of localized ganglioneuroblastoma treated by carboplatin/etoposide for 2 courses and surgery, which developed a serious GHD after 56 months. At present, the child is growing on by GH replacement therapy. We discuss about the hypothesis that GHD may be related to chemotherapy and we report a review of previous published cases.
Schiavetti
Amalia
A
Department of Pediatrics, University of Rome La Sapienza, Rome, Italy. Amaliasc@tiscali.it
Ingrosso
Annapaola
A
Picone
Simonetta
S
Boscherini
Brunetto
B
D000310:Adrenal Gland Neoplasms / Q000188:drug therapy* / Q000601:surgery; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001827:Body Height / Q000187:drug effects; D016190:Carboplatin / Q000009:adverse effects; D005047:Etoposide / Q000009:adverse effects; D018305:Ganglioneuroblastoma / Q000188:drug therapy* / Q000601:surgery; D013006:Growth Hormone / Q000172:deficiency*; D006801:Humans; D007031:Hypothalamus / Q000187:drug effects / Q000473:pathology; D007223:Infant; D008297:Male; D010902:Pituitary Gland / Q000187:drug effects / Q000473:pathology
D005047:Etoposide; D013006:Growth Hormone; D016190:Carboplatin